Compugen (NASDAQ:CGEN) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Compugen Ltd. (NASDAQ:CGEN) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.82 and traded as high as $2.25. Compugen shares last traded at $2.22, with a volume of 407,537 shares.

Analyst Ratings Changes

Separately, Oppenheimer started coverage on Compugen in a report on Monday, January 13th. They issued an “outperform” rating and a $4.00 price target for the company.

Compugen Trading Down 2.2 %

The company has a market cap of $199.01 million, a price-to-earnings ratio of 111.50 and a beta of 2.65. The business has a fifty day moving average of $1.96 and a two-hundred day moving average of $1.82.

Hedge Funds Weigh In On Compugen

Hedge funds have recently made changes to their positions in the company. Oppenheimer & Co. Inc. raised its holdings in shares of Compugen by 75.9% during the third quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 8,350 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of Compugen during the fourth quarter valued at approximately $32,000. Two Sigma Advisers LP raised its holdings in shares of Compugen by 93.6% during the fourth quarter. Two Sigma Advisers LP now owns 35,784 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 17,300 shares during the last quarter. Joel Isaacson & Co. LLC raised its holdings in shares of Compugen by 136.4% during the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 30,000 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Compugen during the fourth quarter valued at approximately $81,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.